Evidence map›Paper›PMID 35163103›Full record

ReviewInternational journal of molecular sciences2022

Gut-Brain Axis as a Pathological and Therapeutic Target for Neurodegenerative Disorders.

Alma Rosa Lezama Toledo, Germán Rivera Monroy, Felipe Esparza Salazar, Jea-Young Lee, Shalini Jain, Hariom Yadav, Cesario Venturina Borlongan

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed, 1 pooled it
8.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

45 citing papers in PubMed, 1 synthesis or guideline pooled it, 78 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. Review
  5. Isoquinoline alkaloids inChinese herbal medicines · 2026
    Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Nutritional and dietary clinical trials for Parkinson's disease: a narrative review.Journal of neural transmission (Vienna, Austria : 1996) · 2025
    Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Article
  17. Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Alma Rosa Lezama ToledoCenter of Excellence for Aging and Brain Repair, Department of Neurosurgery and Brain Repair, Morsani College of Medicine, University of South Florida, 12901 Bruce B Downs Blvd, Tampa, FL 33612, USA.
Germán Rivera MonroyCenter of Excellence for Aging and Brain Repair, Department of Neurosurgery and Brain Repair, Morsani College of Medicine, University of South Florida, 12901 Bruce B Downs Blvd, Tampa, FL 33612, USA.
Felipe Esparza SalazarCenter of Excellence for Aging and Brain Repair, Department of Neurosurgery and Brain Repair, Morsani College of Medicine, University of South Florida, 12901 Bruce B Downs Blvd, Tampa, FL 33612, USA.
Jea-Young LeeCenter of Excellence for Aging and Brain Repair, Department of Neurosurgery and Brain Repair, Morsani College of Medicine, University of South Florida, 12901 Bruce B Downs Blvd, Tampa, FL 33612, USA.
Shalini JainCenter for Microbiome Research, Department of Neurosurgery and Brain Repair, Morsani College of Medicine, University of South Florida, 12901 Bruce B Downs Blvd, Tampa, FL 33612, USA.
Hariom YadavCenter for Microbiome Research, Department of Neurosurgery and Brain Repair, Morsani College of Medicine, University of South Florida, 12901 Bruce B Downs Blvd, Tampa, FL 33612, USA.ORCID 0000-0003-4504-1597
Cesario Venturina BorlonganCenter of Excellence for Aging and Brain Repair, Department of Neurosurgery and Brain Repair, Morsani College of Medicine, University of South Florida, 12901 Bruce B Downs Blvd, Tampa, FL 33612, USA.ORCID 0000-0002-2966-9782
University of South Florida · US

Funding

Gut microbiota-based biomarkers of Alzheimer's disease and its modulation by a ketogenic dietR56AG064075 · NIA · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI YADAV, HARIOM · 2020 to 2021
$1.2M
Microbial therapy improves gut permeability to reduce cognitive decline and Alzheimer’s diseaseRF1AG071762 · NIA · UNIVERSITY OF SOUTH FLORIDA · PI YADAV, HARIOM · 2021 to 2021
$1.1M
Microbial therapy improves gut permeability to reduce cognitive decline and Alzheimer’s diseaseR01AG071762 · NIA · UNIVERSITY OF SOUTH FLORIDA · PI YADAV, HARIOM · 2024 to 2025
$753k
The role of gut microbiota in the efficacy of ketogenic diet to ameliorate Alzheimer's diseaseR21AG072379 · NIA · UNIVERSITY OF SOUTH FLORIDA · PI YADAV, HARIOM · 2021 to 2021
$429k
Metformin and Alzheimer's disease: Underlying Mechanisms that Ameliorate ProgressionR56AG069676 · NIA · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI YADAV, HARIOM · 2020 to 2020
$388k
NIA NIH HHS R01 AG071762NIA NIH HHS R21 AG072379NIA NIH HHS R56 AG064075NIA NIH HHS R56 AG069676NIA NIH HHS RF1 AG071762
6 · The paper itself

Abstract

Human lifestyle and dietary behaviors contribute to disease onset and progression. Neurodegenerative diseases (NDDs), considered multifactorial disorders, have been associated with changes in the gut microbiome. NDDs display pathologies that alter brain functions with a tendency to worsen over time. NDDs are a worldwide health problem; in the US alone, 12 million Americans will suffer from NDDs by 2030. While etiology may vary, the gut microbiome serves as a key element underlying NDD development and prognosis. In particular, an inflammation-associated microbiome plagues NDDs. Conversely, sequestration of this inflammatory microbiome by a correction in the dysbiotic state of the gut may render therapeutic effects on NDDs. To this end, treatment with short-chain fatty acid-producing bacteria, the main metabolites responsible for maintaining gut homeostasis, ameliorates the inflammatory microbiome. This intimate pathological link between the gut and NDDs suggests that the gut-brain axis (GBA) acts as an underexplored area for developing therapies for NDDs. Traditionally, the classification of NDDs depends on their clinical presentation, mostly manifesting as extrapyramidal and pyramidal movement disorders, with neuropathological evaluation at autopsy as the gold standard for diagnosis. In this review, we highlight the evolving notion that GBA stands as an equally sensitive pathological marker of NDDs, particularly in Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis and chronic stroke. Additionally, GBA represents a potent therapeutic target for treating NDDs.

Indexed as

Brain-Gut AxisGastrointestinal MicrobiomeAnimalsHumansNeurodegenerative Diseasesepigeneticsmicrobiomeneurodegenerationneurological disordersstem cells

Identifiers

PMID35163103
PMCPMC8834995
OpenAlexW4205338927

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.